2011-08-24T12:19:46-05:00 2010-12-31 EISNERAMPER LLP 750 THIRD AVENUE NEW YORK NY 100172703 990 2010-01-01 134141945 The Michael J Fox Foundation FOR PARKINSON'S RESEARCH MICH 2125090995 CHURCH STREET STATION PO BOX 780 NEW YORK NY 100080780 Joanne Martz 2011-08-20 2129498700 2010 2016-02-24 21:20:13Z X Todd Sherer Church Street Station PO 780 New York NY 10008 106255595 false X www.michaeljfox.org X 2000 DE THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA. 26 24 68 7 28493 10807 51252077 57111106 0 0 99438 476177 37425 34177 51388940 57621460 34683415 49441851 0 0 5431685 6107055 57500 49600 4137564 4179531 4458038 44352131 60056544 7036809 -2435084 69013965 78224899 44985964 56622447 24028001 21602452 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA. false false 54545702 49441852 TO FUND RESEARCH FOCUSED ON DEVELOPING A CURE FOR PARKINSON'S DISEASE. 54545702 true true false false false false false false false true false false false true true false true false true true true true true true false false true true true false false false false false false false true true false false false false true false false false false true 109 0 true 68 true true true true CA false false false true true false false false false X 26 24 true false false false false false false true true false false true true true true true true true true false AL AK AZ AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X JOANNE MARTZ 2125090995 CHURCH STREET STATION PO BOX 780 NEW YORK NY 100080780 MICHAEL J FOX 2.0 X 0 0 0 HOLLY S ANDERSEN MD 2.0 X 0 0 0 EVA ANDERSSON-DUBIN MD 2.0 X 0 0 0 JON BROOKS 2.0 X 0 0 0 BARRY COHEN 2.0 X 0 0 0 DONNY DEUTSCH 2.0 X 0 0 0 DAVID EINHORN 2.0 X 0 0 0 KAREN FINERMAN 2.0 X 0 0 0 NELLE FORTENBERRY 2.0 X 0 0 0 ALBERT B GLICKMAN 2.0 X 0 0 0 DAVID GOLUB 2.0 X X 0 0 0 MARK L HART III 2.0 X 0 0 0 KATHLEEN KENNEDY 2.0 X 0 0 0 MORTON M KONDRACKE 2.0 X 0 0 0 EDWIN A LEVY 2.0 X 0 0 0 SKIP IRVING 2.0 X 0 0 0 MARC S LIPSCHULTZ 2.0 X 0 0 0 TRACY POLLAN 2.0 X 0 0 0 DOUGLAS I OSTROVER 2.0 X 0 0 0 GEORGE E PRESCOTT 2.0 X X 0 0 0 LILY SAFRA 2.0 X 0 0 0 CURTIS SCHENKER 2.0 X 0 0 0 FREDRICK E ROWE JR 2.0 X 0 0 0 RYAN REYNOLDS 2.0 X 0 0 0 FRED G WEISS 2.0 X 0 0 0 ROBERT W SHACKLETON 2.0 X 0 0 0 KATHERINE H HOOD 40.0 X 470623 0 7753 JOANNE MARTZ 40.0 X 225396 0 19335 Todd Sherer 40.0 X 325496 0 19923 KAREN LEIES 40.0 X 222125 0 24491 DEBORAH W BROOKS 40.0 X 440606 0 25177 John T Grant 40.0 X 145796 0 10189 SHEILA KELLY 40.0 X 146287 0 10164 Brian K Fiske 40.0 X 142653 0 16626 Sohini Chowdhury 40.0 X 136265 0 9863 JAMIE L EBERLING 40.0 X 119754 0 9368 2375001 0 152889 13 false true false SCHANER AND LUBITZ LLC 6391 ARLINGTIN ROAD SUITE 200 BETHESDA MD 20814 Legal Advice 169100 1 6988278 180240 49942588 5398435 57111106 0 232554 232554 0 0 48484078 48240455 243623 243623 243623 358540 6988278 358540 0 0 63633 35140 28493 28493 MISCELLANEOUS REVENUE 5684 5684 5684 57621460 28493 481861 32651054 32651054 0 16790797 16790797 0 1773646 398838 386060 988748 0 3536349 2309989 504014 722346 103054 60866 14136 28052 342782 175679 71459 95644 351224 177956 58497 114771 0 127049 118500 1500 7049 48078 48078 0 49600 49600 0 257571 48905 81226 127440 144442 37849 106593 506088 200590 20646 284852 194155 96116 25303 72736 0 487401 264351 67707 155343 158746 33997 4585 120164 0 1166889 1041364 4671 120854 48548 48548 0 132259 68422 22031 41806 53876 42837 3225 7814 CREDIT CARD & BROKERAGE FEES 186625 186625 OTHER SPECIAL EVENTS EXPENSE 681038 681038 DONATION PROCESSING 94951 94951 MARATHON RUNNER FEES 101964 101964 DUES AND SUBSCRIPTIONS 38693 22535 6607 9551 29665 5057 4985 19623 60056544 54545702 1373278 4137564 4579 1724 16253619 47584331 35167945 28467039 28036 22872 156687 310926 1220999 883939 278893 337060 17091145 1467886 33061 33061 69013965 78224899 1768622 1542594 41763613 53453069 1000196 1000196 453533 626588 44985964 56622447 X 2345986 4194131 21682015 17408321 24028001 21602452 69013965 78224899 X -2435084 9535 X false true true X false X 31063349 37700456 42077867 51259577 57125384 219226633 31063349 37700456 42077867 51259577 57125384 219226633 75581258 143645375 393477 764390 744930 157415 232554 2292766 58519 117 25682 15213 34177 133708 221653107 0.64806 0.69221 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 304571 155482 149089 683445 0 103619 232983 0 84352 337060 0 DEFERRED RENT 349036 DUE TO MJFF CANADA 169493 INTEREST PAYABLE 108059 626588 57621460 60056544 -2435084 -4743 -4743 -2439827 57630995 -4743 14278 9535 57621460 57621460 60070822 14278 14278 60056544 60056544 Scheduel D, Page 3, Question 2: ASC 740-10-05 Footnote Income taxes: The Foundation is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") 740-10-05 relating to accounting and reporting for uncertainty in income taxes. For the Foundation, ASC 740-10-05 is potentially applicable to the incurrence of unrelated business income ("UBIT") attributable to certain of the Foundation's merchandise sales. The adoption of ASC 740-10-05 has not had, and is not expected to have, a material impact on the Foundation's financial statements. RECONCILIATION OF EXPENSES SCHEDULE D, PART XIII, LINE 2D, PAGE 4 EXPENSES ATTRIBUTABLE TO THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH'S CANADIAN ENTITY. true East Asia and the Pacific 0 0 Grantmaking 1303250 Europe (Including Iceland and Greenland) 0 0 Grantmaking 9803216 Middle East and North Africa 0 0 Grantmaking 1241267 North America 0 0 Grantmaking 4318064 South America 0 0 Grantmaking 125000 0 0 0 0 16790797 16790797 Europe/Iceland/Greenland Phase II, randomized, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of moderate to severe L-dopa induced dyskinesia in patients with Parkinson's disease 900000 Europe/Iceland/Greenland AFFITOPE based immunotherapeutic strategies for Parkinson?s disease 475000 North America Testing of davunetide for intranasal administration in mice overexpressing alpha--synuclein 625535 Europe/Iceland/Greenland A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy 500000 East Asia/Pacific Genetic and Environmental Modifiers for LRRK2 Associated PD 624250 East Asia/Pacific Resting state fMRI as a Biomarker for Parkinson's Disease 75000 Europe/Iceland/Greenland Diversity Panel profiling of the LRRK2-IN1 compound 9757 North America Functional Genomic Screening to Identify Novel Regulators of Parkinson's 74772 East Asia/Pacific Optimization of the ELISA for oxidized DJ-1 125000 Europe/Iceland/Greenland Validation of enzymatic activity and neuropathology in G2019S LRRK2-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease 308425 Europe/Iceland/Greenland Investigation of PDE10a Inhibitors for Parkinsons Disease. PI is Bart Ellenbroek. 196515 Europe/Iceland/Greenland In Vivo Assessment of Alpha-Synuclein Secretion 150000 Europe/Iceland/Greenland Lamp-2a as a therapeutic traget in Parkinson's Disease 125000 Europe/Iceland/Greenland Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 37500 Europe/Iceland/Greenland Modulation of the Rho Kinase pathway for improvement of regeneration in PD 248215 Middle East/North Africa Susceptibility genes for antipsychotic-induced extrapyramidal symptoms as modifier genes in Parkinson's disease and L-dopa treatment response 74998 Europe/Iceland/Greenland ASAP study: ASymptomatic LRRK2 mutation carriers and Assessment of factors influencing LRRK2-related PD expression study 745168 Europe/Iceland/Greenland PPMI Clinical Site 257031 Europe/Iceland/Greenland NeuroEPIC Parkinson's disease study 150000 Europe/Iceland/Greenland Deciphering the molecular effects of alpha-synuclein in the nucleus: DNA binding and transcriptional dysregulation 74800 Europe/Iceland/Greenland mTORC1 as a target for the treatment of L-DOPA-induced dyskinesia 249875 Europe/Iceland/Greenland Validation of FKBP inhibitors to target alpha-synuclein pathology in rodent brain 202656 Europe/Iceland/Greenland The Sigma 1 receptor as a target for disease modifying therapies in Parkinson's disease 248406 Europe/Iceland/Greenland The role of mGluR4 in the modulation of L-DOPA-induced motor performance and dyskinesia in a rat model of Parkinson's disease 193385 Europe/Iceland/Greenland Proof-of-concept clinical trial on the use of the 5-HT1A/1B partial agonist Eltoprazine for treatment of L-DOPA-induced dyskinesias 101396 Europe/Iceland/Greenland Development of in vivo models of prion-like transfer of alpha-synuclein 95867 Europe/Iceland/Greenland Down-regulation of GDNF signaling in the a-synuclein model of PD: implications for the use of GDNF in neuroprotective therapy 75000 Europe/Iceland/Greenland Determine the structure of Roco family proteins 74999 North America Intermittent Bilateral Intraputamenal Treatment with GDNF 2100000 Europe/Iceland/Greenland Flibanserin in Levodopa-induced Dyskinesia: MPTP-lesioned Pre-clinical Model 162250 East Asia/Pacific Nasal PD Treatment-Proof-of-Concept 75000 Middle East/North Africa Maintenance of continuous plasma levodopa levels through continuous subcutaneous carbidopa administration 1000000 North America Delayed Start Assessment of Progranulin in a Progressive Rodent Model of Parkinson?s Disease 113630 Europe/Iceland/Greenland The Trondheim LRRK2 cohort program 199875 East Asia/Pacific MJFF-Elan Partnership - OzGene Mouse Generation 64500 Europe/Iceland/Greenland PPMI Clinical Trial Site 257031 Europe/Iceland/Greenland Laboratory phenotyping of Parkinson disease subjects using a multiplex approach 249894 Europe/Iceland/Greenland Ghrelin - a peripheral, preclinical biomarker for Parkinson's disease (PD) 216250 Middle East/North Africa Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup 91670 Middle East/North Africa Biofeedback-based motor learning to ameliorate freezing of gait 74599 Europe/Iceland/Greenland The role of LRRK2 in Wnt signaling in vivo 97896 Europe/Iceland/Greenland Is glucose metabolism perturbed in PD? 50100 Europe/Iceland/Greenland Biochemical characterization of full length human recombinant LRRK1 and LRRK2 - supplemental funding 200000 Europe/Iceland/Greenland Coordinated reset (CR) stimulation of the subthalamic nucleus in the MPTP non-human primate model: Target validation for translating into a clinical trial in PD patients 128810 Europe/Iceland/Greenland Langston Award 2010 25000 North America Increased dopamine turnover as a manifestation of LRRK2 mutation 395105 North America LRRK2 G2019S disease penetrance modifiers 262066 North America Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism 259416 North America The Role of LRRK2 in Neurotransmission 162564 South America Targeting the Unfolded Protein Response (UPR) transcription factor XBP-1 to treat Parkinson's disease. 125000 Europe/Iceland/Greenland Exploiting Ser910/935 phosphorylation and 14-3-3 binding to develop biomarkers for LRRK2 activity 193750 Europe/Iceland/Greenland CDNF (Cerebral Dopamine Neurotrophic Factor) for therapy of Parkinson's disease 515086 Europe/Iceland/Greenland PPMI Clinical Trial Site 257031 North America INCREASED DOPAMINE TRANSPORTER FUNCTION AS AN EARLY PHENOTYPE OF PD, PRIOR TO DOPAMINE NEURON CELL DEATH 74976 North America Functional Analysis of LRRK2: Focus on autophagy 250000 Europe/Iceland/Greenland CSF LYSOSOMAL HYDROLASES' ACTIVITY AS POSSIBLE MARKER OF PARKINSON'S DISEASE 75000 Europe/Iceland/Greenland Prospective validation of risk markers for the development of Parkinson's disease 491132 Europe/Iceland/Greenland Macrophage Precursors as Biomarker for LRRK2-associated Parkinson disease 395000 Europe/Iceland/Greenland Longitudinal Follow up of clinical and neuroimaging signs as well as biomarkers in symptomatic and asymptomatic LRRK2 mtuation carriers in comparison to indiopathic PD and controls 382500 Europe/Iceland/Greenland PPMI Clinical Trial Site 257031 Europe/Iceland/Greenland Immuno-PCR detection of alpha-synuclein phosphorylated at serine-129 as PD biomarker 155785 Europe/Iceland/Greenland Genetic-epidemiological confirmation of top hits of GWAS of Parkinson disease: A large multi-center collaborative study. 74800 50 12 false false false false false false SCHEDULE F PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE THE UNITED STATES: THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made. X X X X true Event Associates Inc 162 WEST 56TH STREET 405 NEW YORK NY 10019 Fundraising Consultants false 0 49600 0 0 49600 0 AL AK AZ AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI FUNNY THING 4692806 4481056 211750 211750 SUNNY THING 875650 823400 52250 52250 3 1778361 1683821 94540 94540 7346817 6988277 358540 358540 358540 true Acadia Pharmaceuticals 3911 Sorrento Valley Blvd San Diego CA 92121 061376651 301015 Development of Nurr1-RXR heterodimer selective ago agonists for Parkinson's disease Adolor Corporation 700 Pennsylvania Drive Exton PA 19341 311429198 363400 Optimization of MOR Antagonists for the Treatment of L-DOPA-Induced Dyskinesias in Parkinson's Disease Amarantus Therapeutics Inc 675 Almanor Avenue Sunnyvale CA 94085 261758388 370717 Comparison and Actions of MANF and GDNF in Rodent Models of Parkinson's Disease Amicus Therapeutics 6 Cedar Brook Drive Cranbury NJ 08512 710869350 499503 Use of the orally administered pharmacological cha chaperone AT3375 to reduce alpha-synuclein levels in the brain of Thy-1 alpha-synuclein mice Arizona State University 1711 S Rural Road Box 6006 Tempe AZ 85287 019669600 501(C)(3) 552273 Morphology specific anti-synuclein nanobodies as t therapeutics for PD Arizona State University 1711 S Rural Road Box 6006 Tempe AZ 85287 019669600 501(C)(3) 156251 Identifying and localizing toxic oligomeric a-syn with morphology specific nanobodies Arizona State University 1711 S Rural Road Box 6006 Tempe AZ 85287 019669600 501(C)(3) 110000 In vivo SPECT Imaging of synuclein aggregation wit with morphology specific antibody based ligands Athersys Inc 3201 Carnegie Avenue Cleveland OH 44115 341830213 140590 Development of an Adult Adherent Allogeneic Stem C Cell Product for Treatment of Parkinson's Disease Avid Radiopharmaceuticals Inc 3711 Market Street Philadelphia PA 19104 201811104 493438 18F-labeled alpha-synuclein ligands for PET imagin imaging of Lewy bodies Baylor College of Medicine The Smith Tower Houston TX 77030 741613878 501(C)(3) 257031 PPMI Clinical Trial Site Beth Israel Deaconess Medical Center 330 Brookline Ave Boston MA 02445 042103881 501(C)(3) 100000 PGC-1 Alpha as a Neuroprotective Target in Parkins Parkinson's Disease Beth Israel Medical Center 10 Union Square East New York NY 10003 135564934 501(C)(3) 14270 Parkinson's Disease, Ashkenazi Jews and LRRK2: a c consortium proposal - SUPPLEMENT Biomer Technology 1047 Serpentine Lane Bldg 200 San Diego CA 94566 6865 Generation of LRRK2 phospho-peptides Board of Regents of the University of Wisconsin Sy 1415 Engineering Drive Madison WI 53706 396006492 501(C)(3) 187476 Novel Antibodies for the Delivery of Parkinson's T Therapeutics Board of Regents of the University of Wisconsin Sy 1111 Highland Avenue Madison WI 53705 396006492 501(C)(3) 90157 Mechanism and Modulation of Alpha-Synuclein Expres Expression Boston University 715 Albany St Boston MA 02118 042103545 501(C)(3) 257031 PPMI Clinical Trial Site CalAsia Pharmaceuticals Inc 11494 Sorrento Valley Road San Diego CA 92121 270641400 549882 Novel, selective and potent brain-penetrant small molecule inhibitors of cytosolic Hsp90 Case Western Reserve University 2103 Cornell Road Cleveland OH 44106 341018992 501(C)(3) 221634 Supplement-Characterization of LRRK2 cellular and signaling pathways Ceregene Inc 9381 Judicial Drive Suite 130 San Diego CA 92121 954838818 2500000 A Sham- Surgery Controlled Phase 2 Trial Testing A AAV2-neurturin (CERE-120) in Moderately Advanced Parkinson Disease Coriell Institute for Medical Research 403 Haddon Avenue Camden NJ 08103 210672684 501(C)(3) 730709 PPMI 2010: BioRepository Cortex Pharmaceuticals Inc 15231 Barranca Parkway Irvine CA 92618 330303583 384849 Assessment of the Neurorestorative Potential of En Enhanced Neurotrophic Support via Positive Glutamatergic Modulation in the MPTP Mouse Model of PD Cortex Pharmaceuticals Inc 15231 Barranca Parkway Irvine CA 92618 330303583 7177 Assessment of the Neurorestorative Potential of En Enhanced Neurotrophic Support via Positive Glutamatergic Modulation in the MPTP Mouse Model of PD-Supplement Covance 8211 SciCor Drive Indianapolis IN 46214 223265977 388784 PPMI Clinical Laboratory Analysis, PPMI study 001 001 Covance 180 Rustcraft Road Indianapolis IN 02026 223265977 155000 Covance LRRK2 ELISA - Using Invitrogen LRRK2 Fragm Fragment, 5 MJFF Epitomics Antibodies, and 1 Neuromab Antibody Covance 180 Rustcraft Road Dedham MA 02026 223265977 59580 DJ-1 analysis in qualification study Covance 180 Rustcraft Road Indianapolis IN 02026 223265977 25000 DJ-1 Reproducibility & Year 1 Analyses in PPMI. Covance 180 Rustcraft Road Indianapolis IN 02026 223265977 16280 Hemoglobin Analysis in Qualification Study Covance 180 Rustcraft Road Dedham MA 02026 223265977 9000 Purification of novel alpha-synuclein polyclonal a antibodies Covance 180 Rustcraft Road Burlingame CA 02026 223265977 6000 Assay optimization to determine suitability of rab rabbit monoclonal antibodies Covance 5858 Horton St Suite 500 Emeryville CA 94608 223265977 5777 Qualification Study - Covance handling of specimen specimens and running ELISA-PPMI prep Covance 180 Rustcraft Road Indianapolis IN 02026 223265977 5640 Covance Protein BCA Analysis Depomed Inc 1360 OBrien Dr Menlo Park CA 94025 943329046 150000 Study to Compare Levodopa/Carbidopa Safety, Tolera Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Gastric Retentive Extended-Release Tablets versus a Reference Extended-Release Tablet in Parkinson's Disease Patients Edmond and Lily Safra International Institute of N Prof Francisco Luciano de Oliveira Durham NC 59066 501(C)(3) 236498 Validation of Dorsal Column Electrical Stimulation Stimulation as a Target for Parkinson's Disease Therapy in 6-OHDA Non-human Primates Emerald BioStructures 7869 NE Day Road West Bainbridge Island WA 98110 911821586 909863 Determine the structure of LRRK2 protein Emerald BioStructures 7869 NE Day Road West Bainbridge Island WA 98110 911821586 25000 PINK1 Protein Generation Emory University 1841 Clifton Road Third Floor Atlanta GA 30329 580566256 501(C)(3) 257031 PPMI Clinical Trial Site Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 166678 LRRK2 Phospho-specific Polyclonal Antibody Generat Generation Epitomics 863 Mitten Road Burlingame CA 94010 64352 LRRK2 rabbit monoclona antibody supplement - scale scale up Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 30872 PINK1 monoclonal rabbit antibody generation Form Formerly: Zou and Chen Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 11325 LRRK2 rabbit monoclonal antibody supplement - addi additional aliquotting and shipping of the LRRK2 antibodies- Formerly: Zou and Chen Gardedam Therapeutics 651 Forest Avenue Palo Alto CA 94301 273699049 75000 Identification of small-molecule stabilizers of DJ DJ-1: biophysical and cellular validation Georgetown University 3970 Reservoir Road Washington DC 20057 530196603 501(C)(3) 74249 SNCA haplotyping in Parkinson's disease and multip multiple system atrophy Harbor Biosciences 4435 Eastgate Mall San Diego CA 92121 133697002 146279 HE3286 as treatment for Parkinson's disease Harvard University 250 Longwood Ave Boston MA 02115 421035800 501(C)(3) 575185 Development of selective LRRK2 inhibitors Harvard University 115 Mill Street Belmont MA 02478 421035800 501(C)(3) 294899 Patient-specific iPS cell-derived neurons and dise disease-associated LRRK2 mutations for Parkinson's disease research Harvard University 77 Avenue Louis Pasteur Boston MA 02115 421035800 501(C)(3) 200000 Physiological and Pathological Implications of the the Unique Subcellular Distribution of LRRK2 Harvard University 240 Longwood Ave Boston MA 02115 421035800 501(C)(3) 124898 Does the Ubiquitin Ligase, Nedd4, Protect Against Alpha-Synucleinopathy? Health Advances LLC 9 Riverside Road Watertown MA 02493 111111111 15000 Industry Landscape Update Indiana University 410 West Tenth Street Indianapolis IN 46202 356001673 501(C)(3) 499819 PROGENI Family Study Invitrogen Corporation 501 Charmany Drive Sunnyvale CA 53719 330373077 72400 LRRK2 Biochemical Studies (Invitrogen/Nichols Coll Collaboration)" Johns Hopkins University 600 North Wolfe St Baltimore MD 21287 520595110 501(C)(3) 257031 PPMI Clinical Trial Site Johns Hopkins University School of Medicine Baltimore MD 21205 520595110 501(C)(3) 75000 Identification and Validation of the modifiers of LRRK2-induced toxicity Massachusetts General Hospital 114 16th St Charlestown MA 02129 042697983 501(C)(3) 249043 Development and screening of contrast agents for i in vivo imaging of Parkinson's Disease Massachusetts General Hospital 114 16th Street Charlestown MA 02129 042697983 501(C)(3) 127324 Generation and characterization of iPS neurons fro from PINK1- and Parkin-linked Parkinson's disease Massachusetts General Hospital 114 Sixteenth Street Charlestown MA 02129 042697983 501(C)(3) 77329 Oligomeric equilibrium in male and female brains w with alpha-synuclein pathology Mayo Clinic 4500 San Pablo Road South Jacksonville FL 32224 593337028 501(C)(3) 229128 Global estimates for the role of LRRK2 variation i in Parkinsons disease susceptibility Mayo Clinic 13400 E Shea Blvd Jacksonville FL 85259 593337028 501(C)(3) 25000 Compensation to Dr Adler re Novel Hypotheses in P PD program McLean Hospital 115 Mill Street Belmont MA 02478 042697981 501(C)(3) 255173 Neuroprotective efficacy of RAB3B in animal models models of alpha-synucleinopathy McLean Hospital 115 Mill Street Belmont MA 02478 042697981 501(C)(3) 132603 Gait disturbances in Parkinson's disease: new link links to alpha-synuclein pathology Mount Sinai School of Medicine One Gustave L Levy Place New York NY 10029 136171197 501(C)(3) 400000 Determining pharmacodynamic biomarkers of LRRK2 ac activity in lymphocytes Mount Sinai School of Medicine One Gustave L Levy Place New York NY 10029 136171197 501(C)(3) 262818 LRRK2 Effects on Neural Differentiation National Institute on Aging 35 Convent Drive Bethesda MD 20892 522038294 501(C)(3) 34375 Biochemical characterization of full length human recombinant LRRK1 and LRRK2 National Institute on Drug Abuse (NIDA)NIH 251 Bayview Blvd Baltimore MD 21224 501(C)(3) 75000 Dopamine D1-D3 receptor heteromer as a new target for Parkinson's disease Neuraltus Pharmaceuticals Inc 2483 E Bayshore Rd Suite 212 Palo Alto CA 94303 201008507 167361 Targeting alpha-synuclein-lipid interactions in pr preclinical Parkinson's disease models. Neuroscience Associates 10915 Lake Ridge Drive Knoxville TN 37934 621540123 349188 Lrrk2 mouse characterization (histology) Neuroscience Associates 10915 Lake Ridge Drive Knoxville TN 37934 621540123 245566 KO rat characterization (histology) Neuroscience Associates 10915 Lake Ridge Drive Knoxville TN 37934 621540123 122783 KO rat characterization (histology)-LRRK2 Northeastern University 360 Huntington Avenue Boston MA 02115 041679980 501(C)(3) 375000 Intranasal GDNF for Parkinson's Disease: Next Ste Steps in Preclinical Development Northern California Institute for Research & Educa 4150 Clement St 114M San Francisco CA 94121 943084159 501(C)(3) 110689 PPMI - 2010 - DTI Core Northwestern University 710 North Lake Shore Drive Chicago IL 60611 362167817 501(C)(3) 257031 PPMI Clinical Trial Site Northwestern University 303 E Superior St Chicago IL 60611 362167817 501(C)(3) 74762 Genetic dissection of Parkinson's disease vulnerab vulnerable dopaminergic neurons population Northwestern University 710 North Lake Shore Drive Chicago IL 60611 362167817 501(C)(3) 58885 A Pilot Phase II Double-Blind, Placebo-Controlled, Placebo-Controlled, Dosage Finding and Tolerability Study of Isradipine as a Disease Modifying Agent in Patients With Early Parkinson's Disease Omeros Corporation 1420 Fifth Avenue Seattle WA 98101 911663741 76442 Selective inhibition of cyclic nucleotide phosphod phosphodiesterase type 7 (PDE7): A novel and efficacious approach to treating Parkinson's disease Oregon Health & Science University 3181 SW Sam Jackson Park Rd Portland OR 97239 931176109 501(C)(3) 257031 PPMI Clinical Trial Site Parexel Glendale Adventist Medical Center Glendale CA 91206 043517643 55156 Parexel Qualification Study PARK IP Translations 134 W 29th Street New York NY 10001 208132576 15000 PPMI Pre-Enrollment: Translation Services Parkinson's Action Network 1025 Vermont Ave NW Suite 1120 Washington DC 20005 943172675 501(C)(3) 250000 PAN Funding 2010 Pfizer Global Research and Development Eastern Point Road Princeton NJ 06340 141396954 300000 Elucidating the Function and Downstream Targets of of LRKK2 PsychoGenics 765 Old Saw Mill River Road Tarrytown NY 10591 150000 Support for your collaboration on 'Proof-of-concep 'Proof-of-concept clinical trial on the use of the 5-HT1A/1B partial agonist Eltoprazine for treatment of L-DOPA-induced dyskinesias. - Linked to Bjorklund CIA 2009 Rush University 1735 W Harrison Str Chicago IL 60612 362174823 501(C)(3) 230025 A rodent model of pathological gambling associated associated with medicated parkinsonian patients. Rush University 1735 West Harrison Street Suite 30 Chicago IL 60612 362174823 501(C)(3) 219185 A monkey alphasynuclein model of Parkinson's disea disease Rush University 1735 West Harrison Street Suite 30 Chicago IL 60612 362174823 501(C)(3) 74999 Protecting innervation: Nmnat1 gene therapy for Pa Parkinson's disease Saint Jude Children's Research Hospital 332 North Lauderdale Memphis TN 38105 162064601 501(C)(3) 88096 Role of H1N1 influenza virus in the etiology of Pa Parkinson's disease. Saint Jude Children's Research Hospital 332 North Lauderdale Memphis TN 38105 162064601 501(C)(3) 75000 Development of a progressive familial mouse model of Parkinson's disease. Sangamo BioSciences Inc 501 Canal Blvd Suite A100 Richmond CA 94804 680359556 895257 Development of a Zinc Finger Protein Therapeutic f for the Potential Treatment of Parkinson's Disease Sigma-Aldrich 2033 Westport Center Drive St Louis MO 63146 841656258 49353 Sigma breeding for rat characterization - Non-LRRK Non-LRRK2 Sigma-Aldrich 2033 Westport Center Drive St Louis MO 63146 841656258 46850 Generation of KO Rat: LRRK1 Sigma-Aldrich 2033 Westport Center Drive St Louis MO 63146 841656258 24676 Sigma breeding for rat characterization- LRRK2 Signum Biosciences 7 Deer Park Drive Monmouth Junction NJ 08852 010615746 164625 Targeting alpha-Synuclein Dephosphorylation via PP PP2A Activation as a Novel PD Therapeutic Signum Biosciences 7 Deer Park Drive Monmouth Junction NJ 08852 010615746 128583 Characterization of PP2A as a Novel Therapeutic Ta Target and a Biomarker of PD SpringBox Ltd 708 Congress Ave Austin TX 78701 196930 Fox Trial Finder Discovery and Build Out Stanford University 318 Campus Drive West Stanford CA 94305 941156365 501(C)(3) 250000 Developing optogenic technology for primates to un understand basal ganglia circuitry Stanford University 269 Campus Drive Stanford CA 94305 941156365 501(C)(3) 103913 Aldehyde Dehydrogenase Activators as Novel Treatme Treatment for Parkinson's disease Sun Health Research Institute 10515 W Santa Fe Drive Sun City AZ 85351 860768795 501(C)(3) 257031 PPMI Clinical Trial Site Sun Health Research Institute 10515 W Santa Fe Drive Sun City AZ 85351 860768795 501(C)(3) 25000 Compensation to Dr Beach re Novel Hypotheses in PD PD program SUNY Downstate Medical Center 450 Clarkson Ave Brooklyn NY 11203 141368361 501(C)(3) 362882 Optimization of optical coherence tomography as a biomarker for Parkinson's disease. Synthonics Inc 1700 Kraft Drive Blacksburg VA 24060 203899302 270850 Metal Complexation with Levodopa to Improve Contin Continuous Dopaminergic Stimulation Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 178520 Elan/MJFF Generation & Characterization (Phase 1) MJFF-6/7/8/9-P3520/P3521/P3522/P3523 Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 126000 LRRK1 constitutive Gene KO mouse; Dual LRRK1/LRRK2 LRRK1/LRRK2 KO Mouse MJFF4/5-P3518/P3519 Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 97150 LRRK2 dead kinase animal model MJFF-10/11/12-P352 MJFF-10/11/12-P3524/P3525/P3526" Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 73673 CJ Li Alpha-Synuclein Rat Housing Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 49115 CJ Li LRRK2 Rat Housing Texas A&M University Department of Pathobiology College Station TX 77843 742245072 501(C)(3) 73200 The role of alpha-synuclein in the pathogenesis of of Parkinson's disease in a rat animal model The Bachmann-Strauss Dystonia & Parkinson Foundati 551 Fifth Avenue New York NY 10176 501(C)(3) 10000 Support of Annual Think Tank The Buck Institute for Research on Aging 8001 Redwood Blvd Novato CA 94945 943030609 501(C)(3) 125000 Pharmacological PHD inhibition as a potential PD n neuroprotectant therapy The Burnham Institute for Medical Research 10901 N Torrey Pines Rd La Jolla CA 92017 510197108 501(C)(3) 208250 Quantitative Analysis of S-Nitrosylated Proteins i in Parkinson's Disease The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(C)(3) 675434 PPMI 2010: Imaging Core The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(C)(3) 336185 PPMI: Leadership Core 2010 The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06511 061582206 501(C)(3) 257031 PPMI Clinical Trial Site The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(C)(3) 15492 PPMI Call Center The Jackson Laboratory 610 Main Street Bar Harbor ME 04609 010211513 501(C)(3) 107315 LRRK2 CJ Li Mouse Characterization Study 20010_BHC 20010_BHCB The Jackson Laboratory 610 Main Street Bar Harbor ME 04609 010211513 501(C)(3) 21000 JAX animal housing project - Cai The Jackson Laboratory 610 Main Street Bar Harbor ME 04609 010211513 501(C)(3) 21000 JAX animal housing project - Yue The Jackson Laboratory 610 Main Street Bar Harbor ME 04609 010211513 501(C)(3) 14000 JAX animal housing project- Cai The Jackson Laboratory 610 Main Street Bar Harbor ME 04609 010211513 501(C)(3) 14000 JAX animal housing project- Richfield The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(C)(3) 496920 Establishing an LRRK2 Signaling Pathway and Assays for Patient Derived Samples The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(C)(3) 257031 PPMI Clinical Trial Site The Scripps Research Institute 5353 Parkside Drive Jupiter FL 33458 330435954 501(C)(3) 500000 Probing the Function of SGK1 and its Relationship to LRRK2 and Parkinson?s Disease Thomas Jefferson University 900 Walnut Street Philadelphia PA 19107 232829095 501(C)(3) 100000 Gremlin-1 a putative VTA-derived Neuroprotective Factor in Parkinson's disease Translational Genomics Research Institute 445 N 5th St Phoenix AZ 85004 753065445 501(C)(3) 75000 MicroRNAs as biomarkers for Parkinson's disease; a comparison of CSF and blood Tufts-New England Medical Center 800 Washington Street Boston MA 02111 501(C)(3) 75000 Generation of a Novel Recombinant Protein Activator of GPR88 University of Alabama at Birmingham 1719 6th Ave South CIRC 516 Birmingham AL 35294 600539600 501(C)(3) 257031 PPMI Clinical Trial Site University of Alabama at Birmingham 1719 6th Ave South CIRC 516 Birmingham AL 35294 600539600 501(C)(3) 128243 LRRK2 Dimerization as Pharmacodynamic Biomarkers of Activity University of Alabama at Birmingham 1719 6th Ave South CIRC 516 Birmingham AL 35294 600539600 501(C)(3) 39836 Validation of VPS41 and TorsinA as Target for Parkinson Disease Therapy University of Arizona College of Medicine Tucson AZ 85724 742652689 501(C)(3) 124999 VEGF-B - a new neurotrophic factor for treatment for Parkinson's disease University of British Columbia 3011-950 West 28th Avenue Jacksonville FL 11111 501(C)(3) 75000 Characterization of PARK16 University of California Irvine 3238 McGaugh Hall Irvine CA 92697 952226406 501(C)(3) 101250 Anti-amyloid oligomer monoclonal antibodies for treatment of Parkinson's Disease University of California Los Angeles 635 Charles E Young Drive South Los Angeles CA 90095 956006143 501(C)(3) 297793 PPMI 2010: Bioinformatics Core University of California Los Angeles 710 Westwood Plaza Los Angeles CA 90095 956006143 501(C)(3) 250000 Kynurenine 3-monooxygenase (KMO) as a target to develop drugs to block progression of PD. University of California Los Angeles 635 Charles E Young Drive South Los Angeles CA 90095 956006143 501(C)(3) 156306 Bioinformatics Core University of California San Diego 9500 Gilman Drive La Jolla CA 92093 952544535 501(C)(3) 350000 Preclinical study in a PD-like transgenic model of a novel isoindole compound that selectively blocks alpha-synuclein oligomerization University of California San Diego 9500 Gilman Drive San Diego CA 92093 952544535 501(C)(3) 257031 PPMI Clinical Trial Site University of Chicago 5841 S Maryland Avenue MC 2030 Chicago IL 60637 362177139 501(C)(3) 77647 Oxidized DJ-1 as a biomarker for Parkinson's disease University of Colorado Denver 12631 East 17th Avenue Aurora CO 80045 846000555 501(C)(3) 477210 Acupuncture as a Symptomatic Treatment for Fatigue in Parkinson's Disease University of Colorado Denver 12700 E 19th Ave Aurora CO 80045 846000555 501(C)(3) 125000 Optimizing metalloporphryins for clinical development University of Florida 100 S Newell Dr Gainesville FL 32610 596002052 501(C)(3) 132777 Regulated rAAV-GDNF to treat Parkinson's disease: Translational research plan University of Iowa 2450 University Capitol Center Iowa City IA 52242 426004813 501(C)(3) 202208 PPMI 2010: Statistics Core University of Michigan 530 Church Street Ann Arbor MI 48109 386006309 501(C)(3) 237242 Treating early cognitive impairments and associated movement control deficits by stimulating alpha4beta2* nAChRs University of Mississippi 2500 N State Street Jackson MS 39216 646008520 501(C)(3) 75000 Increasing Endogenous Neurogenesis Using Neurosteroids: A Novel Therapeutic Strategy to Treat Parkinson's Disease University of Nebraska Medical Center Nebraska Medical Center New Haven CT 68198 470049123 501(C)(3) 75000 Biomarkers and Immunotherapy for Parkinson's Disease University of Pennsylvania 3400 Spruce Street Philadelphia PA 19104 231352685 501(C)(3) 375506 PPMI 2010: Bioanalytics Core - Full Study University of Pennsylvania 330 South 9th Street Philadelphia PA 19104 231352685 501(C)(3) 257031 PPMI Clinical Trial Site University of Pennsylvania 330 S 9th St Philadelphia PA 19107 231352685 501(C)(3) 8000 PPMI Pre-Enrollment Consulting Fee University of Pittsburgh 3501 Fifth Avenue Pittsburgh PA 15260 250965591 501(C)(3) 31037 Male transgenic rat Parkinson's disease model characterization University of Rochester 1351 Mt Hope Avenue Suite 216 Rochester NY 14620 263800000 777550 PPMI 2010: Clinical Core University of Rochester 919 Westfall Road Rochester NY 14618 263800000 501(C)(3) 257031 PPMI Clinical Trial Site University of South Florida 4 Columbia Drive Tampa FL 33606 593102112 501(C)(3) 257031 PPMI Clinical Trial Site University of Texas Health Science Center San Ant 7703 Floyd Curl Drive San Antonio TX 78229 741586031 501(C)(3) 250000 Peroxisome-Proliferator Activated Receptor gamma as a Target for Anti-Dyskinesia Pharmacotherapy University of Utah 295 Chipeta Way Salt Lake UT 84108 876000525 501(C)(3) 47463 Development of a novel zebrafish model to investigate the role of glucocerebrosidase in Parkinson's disease University of Washington 1660 S Columbian Way Seattle WA 98108 916001537 501(C)(3) 257031 PPMI Clinical Trial Site University of Washington 1705 NE Pacific St Seattle WA 98195 916001537 501(C)(3) 15251 Testing whether alpha-synuclein is modified by 4-hydroxy-2-nonenal in the human brain UT Southwestern Medical Center at Dallas (Universi 5323 Harry Hines Blvd Dallas TX 75390 756002868 501(C)(3) 250000 Post-translational modifications of LRRK2 Van Andel Research Institute 333 Bostwick Avenue NE Grand Rapids MI 49503 522000820 501(C)(3) 74901 Circulating microRNAs as Biomarkers for Early Detection of Parkinson's Disease Virginia College of Osteopathic Medicine 1861 Pratt Drive Blacksburg VA 24060 542052107 501(C)(3) 144810 Cerium Oxide Nanoparticles in Treatment of Parkinson's Disease. Washington University in St Louis 660 S Euclid St Louis MO 63110 430653611 501(C)(3) 184045 Validation of Neuroimaging Biomarkers for Nigrostriatal Neurons WIL Research Laboratories 1407 George Road Ashland OH 44805 260564612 319000 Lrrk2 mouse characterization WIL Research Laboratories 1407 George Road Ashland OH 44805 260564612 248467 KO rat characterization WIL Research Laboratories 1407 George Road Ashland OH 44805 260564612 124233 KO rat characterization-LRRK2 XenoPort 3410 Central Expressway Santa Clara CA 95051 943330837 193584 A Novel Prodrug of Acamprosate for Treatment of L-Dopa-Induced Dyskinesias Zaah Technologies 6 Dubon Court Jacksonville FL 11735 680639784 62000 Supplement for database development Clinicogenetic studies of Lrrk2 G2019S in Tunisia Zymes LLC 777 Terrace Avenue Hasbrouck Heights NJ 07604 203153524 476078 Evaluation of the neuroprotectivity ability of Zymes' water-soluble CoQ10 (WS-CoQ10) in animal models of PD; preclinical validation and dose optimization for clinical study 100 58 SCHEDULE I, PART I, LINE 2 PROCEDURES FOR MONITORING GRANT FUNDS IN THE UNITED STATES: THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made. X X X X false false false false false false false false false KATHERINE H HOOD 283344 0 180000 0 7279 0 7350 0 403 0 478376 0 0 0 JOANNE MARTZ 180396 0 45000 0 0 0 6762 0 12573 0 244731 0 0 0 Todd Sherer 225496 0 100000 0 0 0 7350 0 12573 0 345419 0 0 0 KAREN LEIES 179125 0 43000 0 0 0 6664 0 17827 0 246616 0 0 0 DEBORAH W BROOKS 275606 0 165000 0 0 0 7350 0 17827 0 465783 0 0 0 John T Grant 120796 0 15000 0 10000 0 4062 0 6127 0 155985 0 0 0 SHEILA KELLY 130287 0 16000 0 0 0 4389 0 5775 0 156451 0 0 0 Brian K Fiske 129653 0 13000 0 0 0 4053 0 12573 0 159279 0 0 0 Donny Deutsch Board of Directors 60865 Design and Creative Services false SCHEDULE L, PART IV BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS THE FOUNDATION INCURRED DESIGN AND CREATIVE ADVICE EXPENSES OF $60,865 FOR SERVICES RENDERED BY A COMMUNICATIONS, BRAND DEVELOPMENT AND DESIGN AGENCY, THE CHAIRMAN OF WHICH IS A FOUNDATION BOARD MEMBER. THE FOUNDATION ALSO PROVIDED A $15,000 GRANT TO A RESEARCH FIRM FOR THE PURPOSES OF PERFORMING A STUDY OF PARKINSON'S DISEASE, THE PARTNER AND MANAGING DIRECTOR OF WHICH IS A MEMBER OF THE FOUNDATION'S BOARD. X 36 5398435 FAIR VALUE false true false FORM 990, PAGE 1, LINE 1 AND PAGE 2, LINE 1 FINDING THE CURE FOR PARKINSON'S TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION. The Michael J. Fox Foundation for Parkinson's Research is committed to a focused, proactive strategy to do whatever it takes to speed transformative treatments to the nearly five million people living with Parkinson's disease worldwide. We are working to maximize impact by pushing basic discoveries toward clinical trials and strategically targeting resources toward critical research hurdles that other funders cannot or will not prioritize. As the largest non-government funder of Parkinson's research, we stand ready to forge a new model of what a research funding organization can be - stepping up to deliver Parkinson's solutions and, in the process, transforming a flawed biomedical research system in ways that ultimately could impact every life touched by illness or injury. Form 990, Page 6 Governance, Management and Disclosure Line 2: TWO BOARD MEMBERS ARE MARRIED TO ONE ANOTHER. TWO BOARD MEMBERS ARE IN-LAWS. Line 11A: Process for Review of Form 990: The Finance Committee of the Board of Directors, in association with external auditors, approves the annual IRS Form 990 which is then made available to the entire Board before it is filed. Line 12A: Conflict of Interest Policy monitoring: Officers, directors and key employees complete a conflict of interest questionnaire annually. The information is reviewed by the VP, Administration, and conflicts are reviewed with the Board of Directors. Line 15: Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. Line 19: Governing documents are available upon request. - Conflict of interest policy is available upon request. - Financial statements are available at www.michaeljfox.org. MJFF CANADA 365 Bay Street Suite 899 Toronto Ontario CA RESEARCH CA MJFF (US) false false true false false false false false false false false false false false false false false false THE MICHAEL J FOX FOUNDATION (CANADA) C 194518